Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension

Hypertension

Volumn 50, Issue 5, 2007, Pages 977-983

  López, Begoña ^a   Castellano, José M ^b   González, Arantxa ^a   Barba, Joaquín ^b   Díez, Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Echocardiography; Hypertension; Hypertrophy, left ventricular

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOTROPHIN 1; HYDROCHLOROTHIAZIDE; LOSARTAN; ANGIOTENSIN 2 RECEPTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); UNCLASSIFIED DRUG;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SEX RATIO; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLE; DRUG ANTAGONISM; DRUG EFFECT; ECHOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; SYSTOLE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BIOLOGICAL MARKERS; BLOOD PRESSURE; CYTOKINES; DIASTOLE; FEMALE; HEART VENTRICLES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RECEPTOR, ANGIOTENSIN, TYPE 2; SYSTOLE;

EID: 35848929470     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.098111     Document Type: Article

References (38)

1. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension the MAVI Study. Hypertension. 2002;40:470-476.
2. de Simone G, Devereux RB, Kimball TR, Mureddu GF, Roman MJ, Contaldo F, Daniels SR. Interaction between body size and cardiac workload influence on left ventricular mass during body growth and adulthood. Hypertension. 1998;31:1077-1082.
3. Palmieri V, de Simone G, Roman MJ, Schwartz JE, Pickering TG, Devereux RB. Ambulatory blood pressure and metabolic abnormalities in hypertensive subjects with inappropriately high left ventricular mass. Hypertension. 1999;34:1032-1040.
4. Mureddu GF, Pasanisi F, Palmieri V, Celentano A, Contaldo F, de Simone G. Appropriate or inappropriate left ventricular mass in the presence or absence of prognostically adverse left ventricular hypertrophy. J Hypertens. 2001;19:1113-1119.
5. Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C, Nieminen MS, Dahlöf B, de Simone G, Devereux RB. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am Heart J. 2001;141:784-791.
6. de Simone G, Kitzman DW, Palmieri V, Liu JE, Oberman A, Hopkins PN, Bella JN, Rao DC, Arnett DK, Devereux RB. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction. Am J Hypertens. 2004;17:828-833.
7. de Simone G, Palmieri V, Koren MJ, Mensah GA, Roman MJ, Devereux RB. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension. J Hypertens. 2001;19:119-125.
8. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Bonzi B, Poisa P, Belotti E, Agabiti Rosei C, Rizzoni D, Castellano M, Agabiti Rosei E. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2007;49:1077-1083.
9. Pennica D, Swanson TA, Shaw KJ, Kuang WJ, Gray CL, Beatty BG, Wood WI. Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Cytokine. 1996;8:183-189.
10. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR. Expression cloning of cardiotrophin-1, a cyokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci U S A. 1995;92:1142-1146.
11. López N, Díez J, Fortuño MA. Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. J Mol Cell Cardiol. 2006;41:902-913.
12. Ishikawa M, Saito Y, Miyamoto Y, Kuwahara K, Ogawa E, Nakagawa O, Harada M, Masuda I, Nakao K. cDNA cloning of cardiotrophin-1 (CT-1): augmented expressión of CT-1 gene in ventricle of genetically hypertensive rats. Biochem Biophys Res Commun. 1996;219:377-381.
13. Ishikawa M, Saito Y, Miyamoto Y, Harada M, Kuwahara K, Ogawa E, Nakagawa O, Hamanaka I, Kajiyama N, Takahashi N, Masuda I, Hashimoto T, Sakai O, Hosoya T, Nakao K. A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. J Hypertens. 1999;17:807-816.
14. López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, Barba J, Tomás L, Lozano E, Serrano M, Varo N, Beloqui O, Fortuño MA, Díez J. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens. 2005;23:625-632.
15. Pemberton CJ, Raudsepp SD, Yandle TG, Cameron VA, Richards AM. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res. 2005;68:109-117.
16. González A, López B, Martin-Raymondi D, Lozano E, Varo N, Barba J, Serrano M, Díez J. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens. 2005;23:2297-2304.
17. de Simone G, Pasanisi F, Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension. 2001;38:13-18.
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
19. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
20. de Simone G, Devereux RB. Rationale of echocardiographic assessment of left ventricular wall stress and midwall mechanics in hypertensive heart disease. Eur J Echocardiography. 2002;3:192-198.
21. Little WC, Applegate RJ. Congestive heart failure: Systolic and diastolic function. J Cardiothor Vasc Anesth. 1993;7(Suppl 2):2-5.
22. Palmieri V, Bella JN, DeQuattro V, Roman MJ, Hahn RT, Dahlöf B, Sharpe N, Lau CP, Chen WC, Paran E, de Simone G, Devereux RB. Relations of diastolic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study). Am J Cardiol. 1999;84:558-562.
23. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, de Simone G, Mannarino E. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol. 2002;39:2005-2011.
24. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, Schenk J. Development of a novel N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest. 1995;59(Suppl 230):177-181.
25. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001;11:2757-2767.
26. Zolk O, Engmann S, Münzel F, Krajcik R. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab. 2005;288:E1214-E1221.
27. Zolk O, Ng LL, O'Brien RJ, Weyland M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human heart is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation. 2002;106:1442-1446.
28. González A, Ravassa S, Loperena I, López B, Beaumont J, Querejeta R, Larman M, Díez J. Association of depressed cardiac gp130-mediated antiapoptotic pathway with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens. 2007;25:2148-2157.
29. Talwar S, Squire IB, Downie PF, O'Brien RJ, Davies JE, Ng LL. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular dysfunction. Clin Sci. 2000;99:83-88.
30. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T, Wang X, Asai S, Tsuji T, Tanaka H, Saito Y, Kuwahara K, Nakao K, Kinoshita M. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;8:1485-1490.
31. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino S, Kato T, Ogawa S. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem. 2000;275:29717-29723.
32. Funamoto M, hishinuma S, Fujio Y, Matsuda Y, Kunisada K, Oh H, Negoro S, Tone E, Kishimoto T, Yamauchi-Takihara K. Isolation and characterization of the murine cardiotrophin-1 gene: expression and norpeinephrine-induced transcriptional activation. J Mol Cell Cardiol. 2000;32:1275-1284.
33. Hishinuma S. Funamoto M, Fujio Y, Kunisada K, Yamauchi-Takihara K. Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes. Biochem Biophys Res Commun. 1999;264:436-440.
34. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, Rehfeld JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J. 2006;27:3004-3010.
35. Abhayaratna WP, Marwick TH, Becker NG, Jeffery IM, McGill DA, Smith WT. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J. 2006;152:941-948.
36. Asai S, Saito Y, Kuwahara K, Mizuno Y, Yoshimura M, Higashikubo C, Tsuji T, Kishimoto I, Harada M, Hamanaka I, Takahashi N, Yasue H, Nakao K. The heart is a source of circulating cardiotrophin-1 in humans. Biochem Biophys Res Commun. 2000;279:320-323.
37. López N, Díez J, Fortuño MA. Characterization of the protective effects of cardiotrophin-1 aginst non-ischemic death stimuli in adult cardiomyocytes. Cytokine. 2005;30:282-292.
38. Ghosh S, NG LL, Talwar S, Squire IB, Galinanes M. Cardiotrophin-1 protects the human myocardium from ischemic injury. Comparison with the first and second window of protection by ischemic preconditioning. Cardiovasc Res. 2000;48:440-447.